D
Taysha Gene Therapies, Inc. TSHA
$4.65 -$0.01-0.22% NASDAQ
Recommendation
Dividend Power Score
Prev Close
$4.66
Volume
1,998,951
Avg Vol (90D)
3,672,940
Market Cap
$1.28B
Dividend & Yield
--
52-Week Range
$1.05 - $6.02
P/E (TTM)
--
EPS (TTM)
-$0.33
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
Taysha Gene Therapies (TSHA, $4.65) Aroon Indicator entered a Downtrend on February 12, 2026.
2/13/2026 - Tickeron - Stocks
Taysha Gene Therapies (TSHA, $4.67) Moving Average Convergence Divergence (MACD) Histogram turned positive on February 11, 2026
2/12/2026 - Tickeron - Stocks
Taysha Gene Therapies (TSHA, $4.67) entered Uptrend as Momentum indicator ascends above 0 level on Feb 11, 2026
2/12/2026 - Tickeron - Stocks
Taysha Gene Therapies (TSHA, $4.67) Aroon Indicator entered a Downtrend on February 11, 2026.
2/12/2026 - Tickeron - Stocks
Taysha Gene Therapies (TSHA, $4.49) Stochastic Oscillator left the oversold zone on February 10, 2026
2/11/2026 - Tickeron - Stocks
Taysha Gene Therapies (TSHA, $4.49) Aroon Indicator entered a Downtrend on February 10, 2026.
2/11/2026 - Tickeron - Stocks
Taysha Gene Therapies, Inc. $TSHA Holdings Trimmed by Tybourne Capital Management HK Ltd.
2/10/2026 - MarketBeat
Taysha Gene Therapies (TSHA, $4.61) Aroon Indicator entered a Downtrend on February 09, 2026.
2/10/2026 - Tickeron - Stocks
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule
2/6/2026 - TipRanks Financial Blog
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule
2/6/2026 - The Fly
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2/6/2026 - Globe Newswire
Taysha Gene Therapies (TSHA, $4.43) Stochastic Oscillator left the oversold zone on February 05, 2026
2/6/2026 - Tickeron - Stocks
Taysha Gene Therapies (TSHA, $4.54) entered Downtrend as Momentum indicator drops below 0 level on Feb 04, 2026
2/5/2026 - Tickeron - Stocks
Taysha Gene Therapies (TSHA, $4.72) Stochastic Oscillator left the oversold zone on February 03, 2026
2/4/2026 - Tickeron - Technical Analysis
Taysha's REVEAL Trial Progress Puts Rett Gene Therapy And Valuation In Focus
2/3/2026 - Simply Wall St
Taysha Gene Therapies (TSHA, $4.66) entered Uptrend as Momentum indicator ascends above 0 level on Feb 02, 2026
2/3/2026 - Tickeron - Stocks
Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo's Support on Rett Syndrome Program Progress
2/2/2026 - Yahoo! Finance: News
Taysha Gene Therapies (TSHA) Valuation Review After TSHA-102 REVEAL Trial And FDA Alignment Progress
2/2/2026 - Simply Wall St
Taysha Gene Therapies, Inc. $TSHA Shares Sold by SG Americas Securities LLC
2/1/2026 - MarketBeat
Taysha Gene Therapies (TSHA, $4.58) Stochastic Oscillator left the oversold zone on January 29, 2026
1/30/2026 - Tickeron - Stocks
Taysha Gene Therapies (TSHA, $4.58) Aroon Indicator entered a Downtrend on January 29, 2026.
1/30/2026 - Tickeron - Stocks
Here's What Analysts Are Saying About Taysha Gene Therapies (TSHA)
1/29/2026 - Insider Monkey
Taysha Gene Therapies (TSHA, $4.48) Aroon Indicator entered a Downtrend on January 28, 2026.
1/29/2026 - Tickeron - Stocks
Why Taysha Gene Therapies (TSHA) Is Down 6.3% After Rett Trial Progress And Insider Stock Sales - And What's Next
1/28/2026 - Simply Wall St
Taysha Gene Therapies (TSHA, $4.76) Aroon Indicator entered a Downtrend on January 27, 2026.
1/28/2026 - Tickeron - Stocks
Income Statement
Total Revenue (TTM)
$6.31M
EBITDA (TTM)
-$100.98M
EBIT (TTM)
-$102.13M
Net Income (TTM)
-$99.93M
Balance Sheet
Total Assets (Q)
$316.55M
Total Debt (Q)
$69.08M
Total Liabilities (Q)
$97.57M
Book Value Per Share (Q)
$0.7995
Cash Flow
Cash from Operations (TTM)
-$84.68M
Cash from Investing (TTM)
-$344.00K
Cash from Financing (TTM)
$224.68M
Net Change in Cash (TTM)
$139.66M
Filings
Filing Date
Tuesday, November 4, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Feb 23 and 27 (est)
Price History
Loading...
Beta
3.55
7-Day Total Return
-1.48%
30-Day Total Return
-17.84%
60-Day Total Return
12.59%
90-Day Total Return
-2.31%
Year to Date Total Return
-11.43%
1-Year Total Return
190.63%
2-Year Total Return
175.15%
3-Year Total Return
334.58%
5-Year Total Return
-84.18%
52-week Low
Apr 09, 2025 - $1.05
52-week High
Dec 24, 2025 - $6.02
Valuation
Market Cap
$1.28B - Small Cap
Enterprise Value
$1.05B
Price/Sales (TTM)
261.80
Price/Book (Q)
5.83
Dividends and Shares
Shares Outstanding
353.31M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.tayshagtx.com
Phone Number
214 612 0000
Address
3000 Pegasus Park Drive
Dallas, TX 75247
Country
United States
Year Founded
2019
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases... more
NASDAQ 02/12/2026 4:00PM Eastern Quotes delayed